Art. -Nr.: HY-15205

Ganetespib

(Synonyms: STA-9090)

45 Cited Publications

Kundenbewertung

Based on 45 publication(s) in Google Scholar

Ganetespib (STA-9090) is a heat shock protein 90 (HSP90) inhibitor which exhibits potent cytotoxicity in a wide variety of hematological and solid tumor cell lines. Ganetespib has antiangiogenic effects in colorectal cancer mediated through inhibition of HIF-1α and STAT3.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.94%
CAS. Nr.: 888216-25-9
Formel: C₂₀H₂₀N₄O₃
Molecular Weight:364.40

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Ganetespib Chemical Structure

CAS. Nr.: 888216-25-9

Größe

Preis

Verfügbarkeit

Menge

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Massenanfrage

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (45)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

HSP90

Alle HSP Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	15 nM Compound: 6; STA9090	Cytotoxicity against human A375 cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo luminescence assay Cytotoxicity against human A375 cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo luminescence assay	[PMID: 26844689]
HaCaT	IC₅₀	<0.015 μM Compound: Ganetespib	Cytotoxicity against human HaCaT cells assessed as inhibition of cell growth Cytotoxicity against human HaCaT cells assessed as inhibition of cell growth	[PMID: 34742014]
HCT-116	GI₅₀	0.15 μM Compound: 2; STA-9090	Antiproliferative activity against human HCT-116 cells measured after 48 hrs by SRB assay Antiproliferative activity against human HCT-116 cells measured after 48 hrs by SRB assay	[PMID: 32683166]
HeLa	IC₅₀	11.65 nM Compound: 3	Antiproliferative activity against human HeLa cells by MTT assay Antiproliferative activity against human HeLa cells by MTT assay	[PMID: 31839539]
NCI-H2228	IC₅₀	13 nM Compound: 6; STA9090	Inhibition of E6a/b;A20 EML4-ALK (unknown origin) expressed in human NCI-H2228 cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo luminescence assay Inhibition of E6a/b;A20 EML4-ALK (unknown origin) expressed in human NCI-H2228 cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo luminescence assay	[PMID: 26844689]
NCI-H3122	IC₅₀	10 nM Compound: 6; STA9090	Inhibition of E13;A20 EML4-ALK variant (unknown origin) expressed in human NCI-H3122 cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo luminescence assay Inhibition of E13;A20 EML4-ALK variant (unknown origin) expressed in human NCI-H3122 cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo luminescence assay	[PMID: 26844689]
PC-3	IC₅₀	9.3 nM Compound: 3	Antiproliferative activity against human PC3 cells by MTT assay Antiproliferative activity against human PC3 cells by MTT assay	[PMID: 31839539]
U-251	IC₅₀	>10 μM Compound: STA-9090	Antiproliferative activity against human Temozolomide-resistant U-251 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human Temozolomide-resistant U-251 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 37172473]
U-251	IC₅₀	6.84 μM Compound: STA-9090	Antiproliferative activity against human Temozolomide-sensitive U-251 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay Antiproliferative activity against human Temozolomide-sensitive U-251 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	[PMID: 37172473]

In Vitro

Ganetespib causes depletion of receptor tyrosine kinases, extinguishing of downstream signaling, inhibition of proliferation and induction of apoptosis with IC₅₀ values ranging 2-30 nM in genomically-defined NSCLC cell lines. Ganetespib is also approximately 20-fold more potent in isogenic Ba/F3 pro-B cells rendered IL-3 independent by expression of EGFR and ERBB2 mutants^[1]. Ganetespib exhibits potent in vitro cytotoxicity in a range of solid and hematologic tumor cell lines, induces the degradation of known Hsp90 client proteins, displays superior potency to the ansamycin inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG)^[2]. Ganetespib is a potent HSP90 inhibitor, and shown to kill canine tumor cell lines in vitro^[3]. Ganetespib possesses superior JAK/STAT inhibitory activity to both P6 and 17-AAG in terms of potency or duration of response in the HEL92.1.7 cells^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Ganetespib (125 mg/kg, i.v.) accumulates in tumors relative to normal tissues and displays greater in vivo efficacy than 17-AAG without increased toxicity and inhibits proliferation and induces apoptosis in parallel with EGFR depletion in NCI-H1975 xenografts^[1]. Ganetespib (100, 125, 150 mg/kg, i.v.) shows potent antitumor efficacy in solid and hematologic xenograft models of oncogene addiction, as evidenced by significant growth inhibition and/or regressions^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 888216-25-9
Appearance Solid
Molecular Weight 364.40
Formel C₂₀H₂₀N₄O₃
Color White to yellow
SMILES

CN1C2=CC=C(N3C(NN=C3C4=CC(C(C)C)=C(O)C=C4O)=O)C=C2C=C1
Synonyms

STA-9090
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (45)

All WBIHC

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]

2025 Dec 15;10(1):406. PMID: 41392286
Cancer Cell

Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses. [Abstract]

2018 Sep 10;34(3):411-426.e19. PMID: 30146332

Ganetespib purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2018 Sep 10;34(3):411-426.e19. [Abstract]

Immunoblot of HSP70 expression in RD cells after treatment with Ganetespib (GSP) alone or CPT-11+NSC-67574.
Mol Cell

2026 Jan 14;86(2):345-361.e6.
Nat Commun

Reversal of pre-existing NGFR-driven tumor and immune therapy resistance. [Abstract]

2020 Aug 7;11(1):3946. PMID: 32770055
Theranostics

Hsp90 inhibitor HSP990 in very low dose upregulates EAAT2 and exerts potent antiepileptic activity. [Abstract]

2020 Jul 9;10(18):8415-8429. PMID: 32724478
Theranostics

Inhibition of HSP90β Improves Lipid Disorders by Promoting Mature SREBPs Degradation via the Ubiquitin-proteasome System. [Abstract]

2019 Aug 12;9(20):5769-5783. PMID: 31534518
Theranostics

Evaluation of [11C]NMS-E973 as a PET tracer for in vivo visualisation of HSP90. [Abstract]

2019 Jan 1;9(2):554-572. PMID: 30809293
J Exp Clin Cancer Res

High-throughput drug screening identifies EGFR/MAPK pathway targeting sensitivities in organoid models of ovarian carcinosarcoma. [Abstract]

2026 Jan 6;45(1):32. PMID: 41495830
J Control Release

Bispecific T-cell engagers non-covalently decorated drug-loaded PEGylated nanocarriers for cancer immunochemotherapy. [Abstract]

2022 Apr:344:235-248. PMID: 35288168
Cell Death Dis

Dual inhibition of mTOR and HSP90 enhances cisplatin efficacy and overcomes resistance in ovarian cancer. [Abstract]

2026 Mar 27. PMID: 41896217
Cell Death Dis

Amyloid aggregates induced by the p53-R280T mutation lead to loss of p53 function in nasopharyngeal carcinoma. [Abstract]

2024 Jan 11;15(1):35. PMID: 38212344
Cell Death Dis

The antitumor natural product tanshinone IIA inhibits protein kinase C and acts synergistically with 17-AAG. [Abstract]

2018 Feb 7;9(2):165. PMID: 29416003
Cell Rep

SUMOylation and the HSF1-Regulated Chaperone Network Converge to Promote Proteostasis in Response to Heat Shock. [Abstract]

2019 Jan 2;26(1):236-249.e4. PMID: 30605679
Elife

Host proteostasis modulates influenza evolution. [Abstract]

2017 Sep 26;6:e28652. PMID: 28949290
Eur J Med Chem

HSP90/LSD1 dual inhibitors against prostate cancer as well as patient-derived colorectal organoids. [Abstract]

2024 Aug 28:278:116801. PMID: 39241481
Cells

Strong Hsp90α/β Protein Expression in Advanced Primary CRC Indicates Short Survival and Predicts Response to the Hsp90α/β-Specific Inhibitor Pimitespib. [Abstract]

2025 Jun 3;14(11):836. PMID: 40498011
Int J Mol Sci

HSP90 Inhibition Disrupts 27-Hydroxycholesterol-Induced Inflammatory Signaling in Monocytic Cells. [Abstract]

2025 Oct 13;26(20):9963. PMID: 41155259
Int J Mol Sci

Targeting Oncogenic Mutant p53 and BCL-2 for Small Cell Lung Cancer Treatment. [Abstract]

2023 Aug 23;24(17):13082. PMID: 37685889
Front Pharmacol

Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells. [Abstract]

2021 Jul 5:12:651516. PMID: 34290605
Int Immunopharmacol

Ganetespib as an inhibitor of heat shock protein 90 alleviates pulmonary fibrosis by inhibiting the Wnt/β-catenin signaling pathway. [Abstract]

2026 Jan 1;168(Pt 1):115837. PMID: 41248572
Nanomedicine

Nanotechnology-based reformulation of AUY922 mitigates retinal toxicity and retains potent anti-tumor activity. [Abstract]

2026 May 13:102957. PMID: 42134612
Hepatol Commun

Integrin subunit beta 8 contributes to lenvatinib resistance in HCC. [Abstract]

2022 Jul;6(7):1786-1802. PMID: 35238496
Antimicrob Agents Chemother

Identification of Hsp90 Inhibitors with Anti-Plasmodium Activity. [Abstract]

2018 Mar 27;62(4). pii: e01799-17. PMID: 29339390
Cancers (Basel)

Identification of New Vulnerabilities in Conjunctival Melanoma Using Image-Based High Content Drug Screening. [Abstract]

2022 Mar 19;14(6):1575. PMID: 35326726
J Cell Mol Med

Inactivation of CDK12 Enhances Mitochondrial Efficiency to Suppress DNA Damage. [Abstract]

2026 Apr;30(7):e71101. PMID: 41896195
Sci Rep

Functional personalized complex combination nano therapy for osteosarcoma. [Abstract]

2025 Oct 16;15(1):36227. PMID: 41102354
J Biol Chem

Functional Maturation of Cytochromes P4503A4 and 2D6 Relies on GAPDH- and Hsp90-Dependent Heme Allocation. [Abstract]

2024 Feb;300(2):105633. PMID: 38199567
Sci Rep

Identification of a DYRK1A Inhibitor that Induces Degradation of the Target Kinase using Co-chaperone CDC37 fused with Luciferase nanoKAZ. [Abstract]

2015 Aug 3;5:12728. PMID: 26234946

Ganetespib purchased from MedChemExpress. Usage Cited in: Sci Rep. 2015 Aug 3;5:12728. [Abstract]

Ganetespib decreases the DYRK1A protein level. 293T cells are transiently transfected with an expression vector for 3xFLAG-DYRK1A. At 24 h after transfection, the cells are treated with Ganetespib (100 nM) and collected 0 and 8 h after treatment. Total cell lysates are subjected to SDS-PAGE followed by Western blot analysis using antibodies against FLAG and GAPDH. In the control group (DMSO), expression of 3xFLAG-DYRK1A increases at 8 h compared to 0 h, and Ganetespib suppresses this increase of
J Virol

Heat Shock Protein 90 Ensures the Integrity of Rubella Virus p150 Protein and Supports Viral Replication. [Abstract]

2019 Oct 29;93(22):e01142-19. PMID: 31484751
ACS Chem Biol

Transportable, Chemical Genetic Methodology for the Small Molecule-Mediated Inhibition of Heat Shock Factor 1. [Abstract]

2016 Jan 15;11(1):200-10. PMID: 26502114

Ganetespib purchased from MedChemExpress. Usage Cited in: ACS Chem Biol. 2016 Jan 15;11(1):200-10. [Abstract]

Protein level by immunoblotting for HSR target proteins.
Cell Stress Chaperones

Drug-induced keratin 9 interaction with Hsp70 in bladder cancer cells. [Abstract]

2018 Sep;23(5):1137-1142. PMID: 29802537

Ganetespib purchased from MedChemExpress. Usage Cited in: Cell Stress Chaperones. 2018 Sep;23(5):1137-1142. [Abstract]

Western blot analysis of human bladder cancer cell lysates (T24) treated with DMSO, the Hsp90 inhibitor STA9090, the Hsp70 inhibitors VER155008, and MAL3-101 or combinations of the various inhibitors. The blot is probed with a keratin 9 mouse monoclonal antibody
Int J Biochem Cell Biol

Inhibition of HSP90β by ganetespib blocks the microglial signalling of evoked pro-inflammatory responses to heat shock. [Abstract]

2019 Jan:106:35-45. PMID: 30448425

Ganetespib purchased from MedChemExpress. Usage Cited in: Int J Biochem Cell Biol. 2019 Jan:106:35-45. [Abstract]

Levels of HSP70, and phosphorylation and total protein of p38, ERK, JNK, JAK2, STAT3, IκB-α and p65 in total cell lysates are analysed using Western blotting with or without ganetespib (100 nM).

Ganetespib purchased from MedChemExpress. Usage Cited in: Int J Biochem Cell Biol. 2019 Jan:106:35-45. [Abstract]

Confocal immunofluorescence microscopy is performed on cultures that are immunoreacted with antibodies against HSP90β and phospho-Tyr705-STAT3 at 6-h recovery after heat shock with or without ganetespib (100 nM) and HSP90β esiRNA.
J Ultrasound Med

Hepatic Microwave Ablation-Induced Tumor Destruction and Animal End Point Survival Can Be Improved by Suppression of Heat Shock Protein 90. [Abstract]

2020 Jun;39(6):1223-1232. PMID: 31880357
Anticancer Res

Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer. [Abstract]

2019 Apr;39(4):1767-1775. PMID: 30952716

Ganetespib purchased from MedChemExpress. Usage Cited in: Anticancer Res. 2019 Apr;39(4):1767-1775. [Abstract]

Ganetespib suppresses epidermal growth factor receptor (EGFR) and its related downstream pathway molecules in non-small cell lung cancer cells with acquired resistance to EGFR-tyrosine kinase inhibitor. Cells are treated with the indicated concentration of ganetespib for 24 h, and lysates were analyzed by western blot. AKT: protein kinase B; EMT: epithelial-mesenchymal transition; MET: met proto-oncogene; amp: amplification; MAPK: mitogen-activated protein kinase.
bioRxiv

2026 Jun 19.
bioRxiv

NFYA regulates two sequential genome-wide transcriptional activation events during oocyte to embryo transition. [Abstract]

2026 Apr 1:2026.03.30.715371. PMID: 41959188
Research Square Preprint

2024 Oct 10.
bioRxiv

Dominant-negative TP53 mutations potentiated by the HSF1-regulated proteostasis network. [Abstract]

2024 Nov 3:2024.11.01.621414. PMID: 39554167
bioRxiv

2024 August 18.
University of Gothenburg

2023 Jun 27.
McGill University

2022 Sep.
University College London

2019 Oct.
KU LEUVEN

2019 Jun.
University of Texas at Dallas

2018 Jun.

Ganetespib purchased from MedChemExpress. Usage Cited in: University of Texas at Dallas. 2018 Jun.

Immunoblot of HEK293T-REx cells inducibly expressing dn-cHSF1 following pretreatment with vehicle or dox (18 h; 1 pg/mL) and then HSR activation by treatment with arsenite (6 h; 100 pM) or STA-9090 (6 h; 100 nM).

Ganetespib purchased from MedChemExpress. Usage Cited in: University of Texas at Dallas. 2018 Jun.

Immunoblot of HEK293T-Rex cells upon treatment with increasing concentrations of the HSP90 inhibitor STA-9090.
Oncotarget

Combined inhibition of heat shock proteins 90 and 70 leads to simultaneous degradation of the oncogenic signaling proteins involved in muscle invasive bladder cancer. [Abstract]

2015 Nov 24;6(37):39821-38. PMID: 26556859

Ganetespib purchased from MedChemExpress. Usage Cited in: Oncotarget. 2015 Nov 24;6(37):39821-38. [Abstract]

J82 cells are treated with 1 μM STA9090 and 50 μM VER155008 as mono or dual therapy for the time indicated. Lysates are prepared and Western blots probed for cell cycle markers.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 100 mg/mL (274.42 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.7442 mL

13.7212 mL

27.4424 mL

5 mM

0.5488 mL

2.7442 mL

5.4885 mL

10 mM

0.2744 mL

1.3721 mL

2.7442 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.86 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.86 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.86 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 15% Cremophor EL 85% Saline

Solubility: 10 mg/mL (27.44 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Kinase Assay^[1]

Exponentially growing cells are processed in lysis buffer (20 mM HEPES, pH 7.4, 1 mM EDTA, 5 mM MgCl₂, 100 mM KCl) and incubated with increasing concentrations of 17-AAG or ganetespib for 30 min at 4°C, and incubated with biotin-GM linked to Dynabeads MyOne Streptavidin T1 magnetic beads for 1 h at 4°C. Beads are washed three times in lysis buffer and heated for 5 min at 95°C in SDS-PAGE sample buffer. Samples are resolved on 4-12% Bis-Tris gradient gel and Western blots are performed using an anti-HSP90 antibody.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[2]

Cells are grown in 96-well plates based on optimal growth rates determined empirically for each line. Twenty-four hours after plating, cells are treated with the indicated compounds or controls for 72 hours. AlamarBlue is added (10% v/v) to the cells, and the plates are incubated for 3 hours and, then, subjected to fluorescence detection. For the comparative viability/apoptosis assay, NCI-H1975 cells are treated with escalating concentrations of ganetespib for the indicated time periods and subjected to viability analysis via CellTiter Fluor and apoptosis via Caspase Glo 3/7.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

Mice: NCI-H1975 or HCC827 cells are cultured as above and 0.5-1×10⁷ cells are mixed with 50% RPMI 1640/50% Matrigel and subcutaneously injected into the flanks of SCID mice. For efficacy studies, animals with 100-200 mm³ tumors are then randomized into treatments groups of eight. Tumor volumes (V) are calculated by the equation V=0.5236×L×W×T (Length, width, and thickness). Animals are treated by intravenous bolus tail vein injection at 10 mL/kg with ganetespib formulated in 10/18 DRD (10% DMSO, 18% Cremophor RH 40, 3.6% dextrose and 68.4% water). As a measurement of in vivo efficacy, the relative size of treated and control tumors [(%T/C) value] is determined from the change in average tumor volumes of each drug-treated group relative to the vehicle-treated group, or itself in the case of tumor regression. Body weights are monitored daily. For biomarker studies, mice bearing NCI-H1975 xenografts are treated with either a single dose of vehicle or ganetespib, or with 5 daily doses of vehicle or ganetespib, in groups of 3 or 8, and harvested at various time points. Tumors are excised and flash frozen in liquid nitrogen for preparation of protein lysates or fixed in 10% neutral buffered formalin for immunohistochemistry.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (288 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Shimamura T, et al. Ganetespib (STA-9090), a Non-Geldanamycin HSP90 Inhibitor, has Potent Antitumor Activity in In Vitro and In Vivo Models of Non-Small Cell Lung Cancer. Clin Cancer Res. 2012 Jul 17. [Content Brief]

[2]. Ying W, et al. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther. 2012 Feb;11(2):475-84. [Content Brief]

[3]. London CA, et al. Phase I evaluation of STA-1474, a prodrug of the novel HSP90 inhibitor ganetespib, in dogs with spontaneous cancer. PLoS One. 2011;6(11):e27018. [Content Brief]

[4]. Proia DA, et al. Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling. PLoS One. 2011 Apr 14;6(4):e18552. [Content Brief]

[5]. Stewart E, et al. Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses. Cancer Cell. 2018 Sep 10;34(3):411-426.e19. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.7442 mL	13.7212 mL	27.4424 mL	68.6059 mL
	5 mM	0.5488 mL	2.7442 mL	5.4885 mL	13.7212 mL
	10 mM	0.2744 mL	1.3721 mL	2.7442 mL	6.8606 mL
	15 mM	0.1829 mL	0.9147 mL	1.8295 mL	4.5737 mL
	20 mM	0.1372 mL	0.6861 mL	1.3721 mL	3.4303 mL
	25 mM	0.1098 mL	0.5488 mL	1.0977 mL	2.7442 mL
	30 mM	0.0915 mL	0.4574 mL	0.9147 mL	2.2869 mL
	40 mM	0.0686 mL	0.3430 mL	0.6861 mL	1.7151 mL
	50 mM	0.0549 mL	0.2744 mL	0.5488 mL	1.3721 mL
	60 mM	0.0457 mL	0.2287 mL	0.4574 mL	1.1434 mL
	80 mM	0.0343 mL	0.1715 mL	0.3430 mL	0.8576 mL
	100 mM	0.0274 mL	0.1372 mL	0.2744 mL	0.6861 mL

Keywords

Ganetespib

45 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Ganetespib

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Anti-COVID-19 Compound Library

Endoplasmic Reticulum Stress Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Targeted Diversity Library

Anti-Colorectal Cancer Compound Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Extracellular Vesicles (EVs) Compound Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Ganetespib

Alle HSP Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (45)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Ganetespib Related Classifications

Art. -Nr.: HY-15205